Showing 3861-3870 of 8198 results for "".
- Dr. Desai Reflects on AAD's Progress Over Past Yearhttps://practicaldermatology.com/news/Dr-Desai-Reflects-AAD-Progress-Over-Past-Year/2471547/Seemal Desai, MD, FAAD, achieved his dream and propelled the profession forward during his year as American Academy of Dermatology (AAD) president, but work remains to be done, he said in his farewell address at the 2025 AAD Annual Meeting in Orlando, Florida. “This year as your president
- Get In First: A Derm's Case for Early Psoriasis Treatmenthttps://practicaldermatology.com/news/from-aad-2025-a-case-for-early-psoriasis-treatment/2471544/Addressing psoriasis early in its course may lead to prolonged remission and better outcomes, and dermatologists should take note, according to a presentation at the 2025 American Academy of Dermatology Annual Meeting in Orlando.
- Martha Stewart Describes Neurotoxin Preferenceshttps://practicaldermatology.com/news/martha-stewart-describes-neurotoxin-preferences/2471541/BOTOX Cosmetic’s platysma bands indication has a fan in Martha Stewart. The keynote speaker at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, said she visits her dermatologist “once every couple months.” Gesturing to her jaw and neck, Stewart said she ge
- AAD Posters Highlight Positive Data for Roflumilasthttps://practicaldermatology.com/news/AAD-Posters-Highlight-Positive-Data-Roflumilast/2471539/Arcutis Biotherapeutics, Inc., announced new data from two posters shared at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. The first poster presentation details the positive efficacy, patient-reported outcomes, and tolerability for the use of once-daily
- Lebrikizumab Achieves Deep and Sustained Response at 3 Years in ADhttps://practicaldermatology.com/news/Lebrikizuab-Achieves-Deep-Sustained-Response-3-Years-AD/2471538/Lebrikizumab (EBGLYSS) achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis (eczema) at 3 years in the ADjoin long-term extension study presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, Eli Lilly and Company anno
- 2-Year Data: Bimekizumab Can Eliminate Draining Tunnels in HShttps://practicaldermatology.com/news/2-Year-Data-Bimekizumab-Can-Eliminate-Draining-Tunnels-HS/2471535/Two-year data from the BE HEARD trials for bimekizumab-bkzx (BIMZELX®) in moderate-to-severe hidradenitis suppurativa (HS) continued to demonstrate sustained disease control and durable relief from key HS symptoms, including the potential to help prevent long-term structural damage caused by drai
- JAK Inhibitors, Low-Dose Naltrexone Touted as New Options for Nail Lichen Planushttps://practicaldermatology.com/news/JAK-Inhibitors-Low-Dose-Naltrexone-Touted-New-Options-Nail-Lichen-Planus/2471532/JAK inhibitors and low-dose naltrexone appear to be two game-changing options for treatment of nail lichen planus, Shari Lipner, MD, PhD, FAAD, said at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. Dr. Lipner noted the activity of the JAK pathway in lic
- IPC Comorbidities Symposium Covers Depression, Obesity, and Morehttps://practicaldermatology.com/news/IPC-Comorbidities-Symposium-Covers-Depression-Obesity-More/2471517/Comorbidities of psoriasis were the focus of the International Psoriasis Council’s meeting in advance of the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. “Syposium: Preventing Comorbig Disease in Psoriasis” started with presentations on depression and card
- Closing Gaps: Takeda Enhances Diversity in Psoriasis Trialshttps://practicaldermatology.com/news/closing-gaps-takeda-enhances-diversity-in-psoriasis-trials/2471442/Takeda’s phase 3 psoriasis (PsO) clinical trials in the United States achieved success in enhancing racial and ethnic diversity among participants, according to new data from the manufacturer. Psoriasis affects over 7.5 millio
- Phase 1 Trial Shows Safety and Dosing Potential for Combo IL-13 Therapy for ADhttps://practicaldermatology.com/news/phase-1-trial-shows-safety-and-dosing-potential-for-combo-il-13-therapy-for-ad/2471401/Apogee Therapeutics has reported positive interim results from a Phase 1 trial evaluating APG990, a subcutaneous, extended half-life monoclonal antibody targeting OX40L, for inflammatory and immunological conditions such as atopic dermatitis (AD), according to a pre